Abstract: The invention relates to the field of analgesics. According to the invention, a kit or composition, particularly a pharmaceutical composition or a pharmaceutical kit, is provided, comprising a nanocarrier which is a hyperbranched polymer, such as a dendritic polymer or dendrimer, preferably having a molecular weight of 1,000-100,000 g/mol, and an analgesic which, when administered without nanocarrier, has both peripheral and central analgesic effect, preferably an opioid such as nalbuphine. According to the invention, the analgesic in this composition mainly or exclusively has a peripheral effect and thus reduces side effects triggered by the activation of central or intestinal opioid receptors. It is used for the treatment of peripheral pain and/or inflammation. The invention also relates to particularly suitable nanocarriers.

Abstract: The present invention relates to compositions, in particular for the treatment of hyperthyreosis (also designated hyperthyroidism), especially in cats. These compositions are formulated for transdermal administration of an active substance and may, for example, be applied into the auricle (or pinna) of the cat. They comprise an active agent such as methimazole (or 2-mercapto-1-methylimidazole) or carbimazole, at least one wax, at least one fatty oil, and optionally an emulsifier. As emulsifier a nanocarrier may be used, for example. Unimolecular nanocarriers of dendritic structure are preferred, wherein the nanocarrier comprises a dendritic core and at least two shells, wherein an inner shell is coupled to the dendritic core via a first linker, and an outer shell is coupled to the inner shell via a second linker. In one embodiment, the composition is provided as a stick, in another, a semi-solid formulation in a suitable applicator which may contain one or more dosage units.